

modified antibody has an increased affinity for FcRn compared to the affinity to FcRn of an antibody having a wild type human IgG constant domain.

**38.** The pharmaceutical composition of claim **17**, wherein said person is a person 60 years and older, 65 years and older, 70 years and older, 75 years and older, 80 years and older, 85 years and older or 90 years and older.

\* \* \* \* \*